[
    [
        {
            "time": "",
            "original_text": "泰格医药(300347.SZ)：持股5%以上股东曹晓春质押145万股及解押315万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "股东",
                    "质押",
                    "解押"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)：持股5%以上股东曹晓春质押145万股及解押315万股",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[路演]泰格医药：公司目前海外多中心临床业务主要集中在亚太地区",
            "features": {
                "keywords": [
                    "泰格医药",
                    "海外业务",
                    "亚太地区"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[路演]泰格医药：公司目前海外多中心临床业务主要集中在亚太地区",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[路演]泰格医药：疫情影响主要集中在2月份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "疫情",
                    "影响",
                    "2月份"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[路演]泰格医药：疫情影响主要集中在2月份",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[路演]泰格医药：近几年公司订单情况良好",
            "features": {
                "keywords": [
                    "泰格医药",
                    "订单",
                    "良好"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[路演]泰格医药：近几年公司订单情况良好",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【兴证医药】行业比较优势突出，细分领域分化明显 — 医药生物上市公司2019年报及2020年一季报小结",
            "features": {
                "keywords": [
                    "兴证医药",
                    "行业优势",
                    "细分领域",
                    "年报",
                    "季报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【兴证医药】行业比较优势突出，细分领域分化明显 — 医药生物上市公司2019年报及2020年一季报小结",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "赴港记 | 泰格医药在港IPO欲募资10亿美元 曾被曝出造假等丑闻 欺诈造假",
            "features": {
                "keywords": [
                    "泰格医药",
                    "赴港IPO",
                    "募资",
                    "造假",
                    "丑闻"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "赴港记 | 泰格医药在港IPO欲募资10亿美元 曾被曝出造假等丑闻 欺诈造假",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "我国CRO产业要素在2020年全球产业链转移背景下有何变化？",
            "features": {
                "keywords": [
                    "CRO产业",
                    "全球产业链",
                    "转移",
                    "变化"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "我国CRO产业要素在2020年全球产业链转移背景下有何变化？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "泰格医药拟赴港募资约10亿美元 CRO企业在A+H市场备受欢迎",
            "features": {
                "keywords": [
                    "泰格医药",
                    "赴港募资",
                    "CRO企业",
                    "A+H市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药拟赴港募资约10亿美元 CRO企业在A+H市场备受欢迎",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]